Table 4 The association between ERCC1 polymorphism and clinical outcomes

Goekkurt 2006 [11]

CC: 2/5; CT+TT: 11/44

NR

NR

Ruzzo 2006 [14]

CC: 21/38; CT+TT: 49/137

NR

NR

Park 2011 [18]

CC: 35/64; CT+TT: 23/44

TC/CC: 0.94 (0.556, 1.587); TT/CC: 1.918 (0.748, 4.919)

NR

Han 2010 [19]

CC: 12/23; CT+TT: 9/15

NR

NR

Stocker 2009 [20]

NR

CT/CC: 0.72 (0.40, 1.31); TT/CC: 1.07 (0.59, 1.95)

NR

Seo 2009 [21]

CC: 11/42; CT+TT: 7/33

NR

NSS

Liu 2011 [22]

NR

(CT+TT)/CC: 2.388 (1.448, 3.937)

NR

Huang 2009 [26]

NR

(CT+TT)/CC: 1.072 (0.620, 1.855)

NR

Keam 2008 [30]

CC: 17/40; CT+TT: 15/33

(CT+TT)/CC: 1.251 (0.68, 2.302)

NR

Goekkurt 2009 [31]

CC: 9/21; CT+TT: 43/113

NR

NSS

Combined analysis (OR/HR, 95CI %)

OR: (CT+TT)/CC

HR: (CT+TT)/CC

___

Total (Palliative chemotherapy): 0.77 (0.54, 1.11);

Total: 1.5 (0.90, 2.49)

Palliative subgroup: 1.77 (0.94, 3.33);

RECIST subgroup: 0.89 (0.52, 1.53);

Adjuvant subgroup: 1.07 (0.62, 1.85);

WHO subgroup: 1.13 (0.45, 2.85);

All studies reported the data were

Others subgroup: 0.56 (0.32, 1.00);

Asian.

Asian subgroup: 0.98 (0.61, 1.59);

European subgroup: 0.56 (0.32, 0.97)